Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double‐blind controlled trial

Chams‐Davatchi, Cheyda; Barikbin, Behrooz; Shahram, Farhad; Nadji, Abdolhadi; Moghaddassi, Maryam; Yousefi, Maryam; Davatchi, Fereydoun

doi:10.1111/j.1756-185x.2010.01531.x

Cited by 31 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This compound binds to ulcerated tissue and forms a barrier and augments ulcer healing. Recent controlled studies suggest that pimecrolimus, a topical immunomodulator, twice a day seems to be safe and efficient in the treatment of genital ulcers, by accelerating the healing process and shortening the pain duration [28, 29]. Amlexanox accelerate the healing and decreases the pain severity of oral ulcers.…”

Section: Treatmentmentioning

confidence: 99%

“…Antimicrobial agents [20–26], sucralfate [27] and corticosteroids [19] especially in OUs, and pimecrolimus [28, 29] in GUs can be selected as 1st-line topical treatment choices. Anti-inflammatory agents, amlexanox, anaesthetics, and silver nitrate [30–33] are other alternatives for topical treatment of mucocutaneous lesions.…”

Section: Evidenced-based Algorithmic Treatment Approach In Behçet'mentioning

confidence: 99%

See 1 more Smart Citation

New Evidence-Based Treatment Approach in Behçet's Disease

Alpsoy

2012

Pathology Research International

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic, relapsing, and debilitating systemic vasculitis of unknown aetiology with the clinical features of mucocutaneous lesions, ocular, vascular, articular, neurologic, gastrointestinal, urogenital, and pulmonary involvement. The disease is much more frequent along the ancient “Silk Route” extending from Eastern Asia to the Mediterranean basin, compared with Western countries. The disease usually starts around the third or fourth decade of life. Male sex and a younger age of onset are associated with more severe disease. Although the treatment has become much more effective in recent years, BD is still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of irreversible organ damage. Therefore, close monitoring, early, and appropriate treatment is mandatory to reduce morbidity and mortality. The treatment is mainly based on the suppression of inflammatory attacks of the disease using immunomodulatory and immunosuppressive agents. In this paper, current state of knowledge regarding the therapeutic approaches is outlined. To provide a rational framework for selecting the appropriate therapy along the various treatment choices, a stepwise, symptom-based, evidence-based algorithmic approach was developed.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Evidenced-based Algorithmic Treatment Approach In Behçet'mentioning

confidence: 99%

New Evidence-Based Treatment Approach in Behçet's Disease

Alpsoy

2012

Pathology Research International

View full text Add to dashboard Cite

show abstract

“…There does however seem to be a genetic component involved, as first degree relatives of the affected patients are often affected in more than expected proportion for the general population [30]. Pimecrolimus is safe and effective for the treatment of BD genital ulcers and accelerates the healing process [31]. …”

Section: Resultsmentioning

confidence: 99%

Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases

Rodríguez-Cerdeira

Sánchez-Blanco

Molares-Vila

2012

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Inflammation-driven immune dysfunction supports the development of several chronic human disorders including skin diseases. Nonantibiotic macrolides have anti-inflammatory and/or immunomodulatory activity that suggests the exploitation of these in the treatment of skin diseases characterized by inflammatory disorders. Materials and Methods. We performed an extensive review of the nonantibiotic macrolide literature published between 2005 and 2012, including cross-references of any retrieved articles. We also included some data from our own experience. Results. Calcineurin antagonists such as tacrolimus and ascomycins (e.g., pimecrolimus) act by inhibiting the activation of the nuclear factor for activated T cells (NFAT). There are new applications for these macrolides that have been available for several years and have been applied to skin and hair disorders such as atopic dermatitis, oral lichen planus, vitiligo, chronic autoimmune urticaria, rosacea, alopecia areata, pyoderma gangrenosum, Behcet's disease, neutrophilic dermatosis, and lupus erythematosus. We also reviewed new macrolides, like rapamycin, everolimus, and temsirolimus. In addition to the literature review, we report a novel class of nonantibiotic 14-member macrocycle with anti-inflammatory and immunomodulatory effects. Conclusions. This paper summarizes the most important clinical studies and case reports dealing with the potential benefits of nonantibiotic macrolides which have opened new avenues in the development of anti-inflammatory strategies in the treatment of cutaneous disorders.

show abstract

“…Tacrolimus and pimecrolimus are macrolide antiinflammatory drugs with potent immunosuppressive activity [48–51]. Tacrolimus is used for its capacity to inhibit T-cell cytokines, such as IL-2, IL-4, and TNF- α .…”

Section: Novel Treatment Of Behçet's Diseases Based On Immunopathomentioning

confidence: 99%

“…Pimecrolimus cream shortens the pain duration in genital ulcers [50]. In another clinical study, pimecrolimus versus placebo was used in genital ulcer of BD and also pimecrolimus was found safe and efficient in the treatment of genital ulcers, by accelerating the healing [51]. …”

Section: Novel Treatment Of Behçet's Diseases Based On Immunopathomentioning

confidence: 99%

Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

Köse

2012

Pathology Research International

View full text Add to dashboard Cite

Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet's diseases and novel treatment modalities will be discussed.

show abstract

Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double‐blind controlled trial

Abstract: Pimecrolimus is safe and efficient in the treatment of BD genital ulcers, by accelerating the healing process.

Cited by 31 publications

References 16 publications

New Evidence-Based Treatment Approach in Behçet's Disease

New Evidence-Based Treatment Approach in Behçet's Disease

Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases

Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

Contact Info

Product

Resources

About